Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

NCT02163915 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
47
Enrollment
INDUSTRY
Sponsor class

Stopped To allow evaluation of emerging non-clinical data (see detailed description below)

Conditions

Interventions

Sponsor

Takeda